Core Viewpoint - U.S. drugmaker Regeneron Pharmaceuticals exceeded analysts' profit expectations for the fourth quarter, driven by robust demand for its eczema treatment, Dupixent [1] Company Summary - Regeneron Pharmaceuticals reported a strong performance in the fourth quarter, attributed to the high demand for its eczema treatment, Dupixent [1]

Core Insights - Regeneron Pharmaceuticals reported strong financial performance in 2025, driven by four blockbuster medicines and a promising late-stage clinical portfolio [2][3] - The company achieved significant label expansions and new approvals for its key products, including EYLEA HD and Dupixent, enhancing their commercial potential [2][4] Financial Highlights - Total revenues for Q4 2025 were $3,884 million, a 3% increase from Q4 2024, while full year revenues reached $14,343 million, up 1% from 2024 [3][14] - GAAP net income for Q4 2025 was $845 million, down 8% from Q4 2024, with a full year GAAP net income of $4,505 million, an increase of 2% [3][14] - Non-GAAP net income for Q4 2025 was $1,249 million, a decrease of 10% from Q4 2024, while full year non-GAAP net income was $4,888 million, down 8% [3][14] Business Highlights - Dupixent global net sales increased by 34% in Q4 2025 to $4.9 billion, with full year sales rising 26% to $17.8 billion [4][14] - EYLEA HD U.S. net sales surged 66% in Q4 2025 to $506 million, with full year sales increasing 36% to $1.6 billion [4][14] - Libtayo received additional approvals and is now the leading immunotherapy for non-melanoma skin cancers [2][4] Pipeline Progress - Regeneron has approximately 45 product candidates in clinical development, with several key updates expected in 2026 [4][10] - Upcoming milestones include FDA decisions for EYLEA HD pre-filled syringe and Dupixent's regulatory submissions for new indications [13][28] Capital Allocation - The company repurchased $671 million of its common stock in Q4 2025 and $3.5 billion for the full year, with $1.5 billion remaining for future repurchases [26] - A cash dividend of $0.94 per share was declared, payable on March 5, 2026 [27] 2026 Financial Guidance - Regeneron projects GAAP R&D expenses between $6.450 billion and $6.680 billion for 2026, with non-GAAP R&D expenses expected to be between $5.900 billion and $6.100 billion [28][29] - The company anticipates a GAAP effective tax rate of 12% to 14% for 2026 [28]

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.Analysts expect the Tarrytown, New York-based company to report quarterly earnings at $10.74 per share, down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron Pharmaceuticals' quarterly revenue is $3.79 billion, versus $3.79 billion a year earlier, according to data from Benzinga Pro.On Dec. 1, Regeneron Pharmaceuticals and Tessera Th ...

Earnings Results - Regeneron Pharmaceuticals is set to release its fourth-quarter earnings results on January 30, with analysts expecting earnings of $10.74 per share, a decrease from $12.07 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $3.79 billion, unchanged from the previous year [1] Collaboration Announcement - On December 1, Regeneron Pharmaceuticals announced a global collaboration with Tessera Therapeutics to develop and commercialize TSRA-196 [2] - Following the announcement, Regeneron Pharmaceuticals shares experienced a slight decline of 0.2%, closing at $749.44 [2] Analyst Ratings - Benzinga provides access to the latest analyst ratings for Regeneron Pharmaceuticals, allowing readers to sort by various criteria such as stock ticker and rating change [2]

Group 1 - Sanofi reported adjusted earnings of 91 cents per share on $13.5 billion in fourth-quarter sales, exceeding analysts' expectations of 84 cents per share and $13.57 billion in sales [1][1][1] - The company's earnings per share increased from 68 cents in the same period last year, while sales rose from $11.89 billion [1][1][1] Group 2 - Sanofi's stock experienced a slight increase following the earnings report, indicating a positive market reaction to the results [1][1][1]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% [4][10] - For the full year 2025, sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates, which is at the upper end of the guidance [11][12] - Business EPS growth was strong at 26.7%, with business EPS excluding share buyback growing by 12.2% [10][12] - Free cash flow returned to strong levels at EUR 8.1 billion, representing 18.5% of sales, with a target to sustainably reach at least 20% in the medium term [12][13] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines grew by 34% in 2025, with full year sales of EUR 1.8 billion for RSV protection [4][10] - Dupixent achieved EUR 4.2 billion in Q4 and EUR 15.7 billion in annual sales, with over 30% increase in patients [5][10] - ALTUVIIIO reached blockbuster status with EUR 1.2 billion in full year sales, and Ayvakit reached $725 million in annual pro forma sales [4][10] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full year sales reaching EUR 7.9 billion [5][6] - Beyfortus grew 9.5% to EUR 1.8 billion, driven by geographic expansion [5][6] - The company expanded its market presence in China, obtaining approvals for several global and China-only medicines [22] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma company, focusing on innovation and strategic acquisitions [3][7] - The completion of the Opella transaction allowed reinvestment into business development and M&A opportunities [3][12] - The company aims to increase its dividend for the 31st consecutive year and has completed a EUR 5 billion share buyback program [15] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver profitable growth close to 2025 levels, with high single-digit growth in sales [15][16] - The company anticipates a slight decline in vaccine sales in 2026 and plans to optimize its portfolio through divestments [16] - Management highlighted the importance of maintaining a strong capital structure and financial flexibility for future growth opportunities [13][15] Other Important Information - The company co-developed PAS 2090, a global standard for measuring and reducing the environmental impact of medicines and vaccines [8] - The company is focused on expanding its pipeline with strategic acquisitions, including Dynavax Technologies Corporation [7][63] Q&A Session Questions and Answers Question: Can you elaborate on the Dupixent rollout since CSU and COPD? - The Dupixent rollout has shown strong performance with 25% growth year-over-year, culminating in a 32% growth in Q4, driven by new indications [29][30] Question: What is the outlook for Beyfortus in 2026? - Beyfortus had a 9% increase in 2025, and while it's early to provide specific guidance for 2026, the company is optimistic about its performance [33][34] Question: Can you provide more detail on the Amlitelimab case related to Kaposi sarcoma? - Kaposi sarcoma is associated with herpes virus, and while there is a theoretical risk with immunomodulators, the benefit-risk profile remains favorable [46][48] Question: What are the prospects for growth and earnings looking forward to 2027? - The company expects a negative impact from the loss of R&D reimbursement from Regeneron, but this will be offset by increased Amvutra royalties [53][54]

Core Viewpoint - Regeneron Pharmaceuticals is a leading biotechnology company focused on developing innovative medicines for serious diseases, competing with major players like Amgen and Biogen [1] Financial Performance - Regeneron is set to release its quarterly earnings on January 30, 2026, with an estimated EPS of $10.56 and revenue of approximately $3.78 billion, while the Zacks Consensus Estimate projects revenues at $3.82 billion [2] - Historically, Regeneron has exceeded earnings estimates in three of the last four quarters, with an average surprise of 21.81% [2] Product Focus - The upcoming earnings report will emphasize profits from the asthma drug Dupixent and sales of Eylea HD, with Eylea's legacy sales declining due to competition, but Eylea HD expected to boost overall franchise revenues [3] - Strong demand for Dupixent across multiple indications is anticipated to drive solid profit growth, offsetting the decline in Eylea sales [3] Stock Performance - Regeneron's stock has increased over 16% since the last analysis, reinforcing a Buy rating, although it is still trading below its all-time high of approximately $1,200 reached in August 2024 [4] - The earnings report could potentially drive the stock price higher if results exceed expectations, while a miss might lead to a decline in stock value [4] Valuation Metrics - Regeneron has a price-to-earnings (P/E) ratio of approximately 17, indicating investors are willing to pay $17 for every $1 of earnings [5] - The company's price-to-sales ratio stands at about 5.44, and the enterprise value to sales ratio is roughly 5.46, indicating consistent valuation metrics [5] - Regeneron demonstrates a solid financial position with a low debt-to-equity ratio of 0.087 and a strong current ratio of 4.06 [5][6]

Core Insights - Investors are focusing on profits from the asthma drug Dupixent and sales of Eylea HD as Regeneron Pharmaceuticals prepares to report its fourth-quarter 2025 results on January 30, 2026, with revenue estimates at $3.82 billion and earnings at $10.56 per share [1] Earnings Performance - Regeneron has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 21.81%, including a 25.32% beat in the last reported quarter [2] Earnings Prediction - The earnings model predicts a likely earnings beat for Regeneron, supported by a positive Earnings ESP of +0.82% and a Zacks Rank of 1 (Strong Buy) [3][4] Product Sales Overview - Eylea, a key revenue driver, has faced sales pressure due to competition from Vabysmo, with preliminary sales of $577 million in the U.S. for Q4 [5][6] - Eylea HD, a higher dose version, has seen strong initial uptake with sales of $506 million in the U.S. for the quarter, following FDA approval for new dosing options [7][8] Dupixent Performance - Dupixent is expected to show solid growth in Q4, driven by strong demand across multiple indications, likely offsetting the decline in Eylea sales [10] Diversification Strategy - Regeneron is working to diversify its revenue base beyond Eylea, focusing on building its oncology franchise, which includes Libtayo and the newly approved Lynozyfic [11] - Libtayo's sales growth has been bolstered by recent label expansions, with current sales estimates at $482 million [12] Share Repurchase Program - A decrease in outstanding shares due to a $3.0 billion share repurchase program is expected to positively impact the bottom line, with $2.156 billion remaining for repurchases as of September 30, 2025 [15] Stock Performance - Regeneron's shares have increased by 12.2% over the past year, compared to the industry's growth of 17.1% [16]

Group 1 - The pharmaceutical industry is currently at a crucial juncture, with significant earnings reporting scheduled for January 30th following the J.P. Morgan Healthcare Conference in mid-January [1] - The Haggerston BioHealth investing group, led by a biotech consultant with over 5 years of experience, provides detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [2] - The group offers insights into catalysts for investment decisions, including buy and sell ratings, product sales forecasts, and integrated financial statements [2]

Core Viewpoint - The comparison between Regeneron (REGN) and Illumina (ILMN) indicates that REGN presents a better value opportunity for investors at this time due to its stronger earnings outlook and more attractive valuation metrics [1][3][7]. Valuation Metrics - REGN has a Zacks Rank of 1 (Strong Buy), while ILMN has a Zacks Rank of 3 (Hold), suggesting a stronger improvement in REGN's earnings outlook [3]. - REGN's forward P/E ratio is 17.17, significantly lower than ILMN's forward P/E of 30.42, indicating that REGN may be undervalued relative to ILMN [5]. - The PEG ratio for REGN is 1.56, compared to ILMN's PEG ratio of 2.56, further supporting REGN's valuation attractiveness [5]. - REGN's P/B ratio stands at 2.56, while ILMN's P/B ratio is much higher at 9.88, reinforcing the notion that REGN is a better value stock [6]. - REGN has been assigned a Value grade of B, whereas ILMN has a Value grade of C, highlighting the relative valuation strength of REGN [6]. Investment Conclusion - Given the stronger estimate revision activity and more favorable valuation metrics, value investors are likely to favor REGN over ILMN as the superior investment option at this time [7].